At the 2024 Precision Health Summit, the session Precision Meets Personalization: Democratizing Healthspan for All, led by Willie Reaves, Head of Public Engagement at Cellino, will take place on October 10 from 12:00 pm to 12:30 pm. This session will explore how advancements in AI-driven biomanufacturing technology are poised to revolutionize the development of personalized regenerative medicines and extend healthspan for millions of people worldwide.

Reaves will discuss Cellino’s mission to democratize access to personalized therapies for chronic degenerative conditions such as Parkinson’s, age-related macular degeneration, and heart disease. Central to this mission is Cellino’s innovative platform, which leverages AI, label-free imaging, and high-speed laser editing to automate the complex process of manufacturing patient-specific cells. These technologies are designed to overcome the scalability issues that have long hindered the widespread adoption of regenerative medicine.

By creating a scalable, automated system for producing personalized human cells, Cellino aims to make these potentially curative therapies more accessible and affordable. Reaves will explore how this groundbreaking approach could enable healthier, longer lives for all by offering safer, patient-specific treatments at scale. This session will provide valuable insights for healthcare innovators, investors, and leaders on the future of personalized medicine and its potential to transform global healthcare.

buff.ly/3zEv3MP ... See MoreSee Less

At the 2024 Precision Health Summit, the session Precision Regenerative Medicine Manufacturing with AI, led by Matthias Wagner, Co-Founder and CTO of Cellino, will take place on October 10 from 11:30 am to 12:00 pm. This session will delve into how AI is transforming the manufacturing process for patient-specific regenerative medicine, offering a glimpse into the future of personalized healthcare.

Wagner’s work at Cellino represents a significant advancement in the field of regenerative medicine, where the promise of stem cell-derived therapies has been tempered by the challenges of scalability and high variability in production. Traditional manufacturing processes for autologous cells—derived from a patient’s own body—are complex, manual, and costly. Cellino aims to disrupt this model by using an AI-driven platform that automates cell reprogramming, expansion, and differentiation, thus overcoming the bottlenecks that have plagued the industry.

Cellino’s platform leverages advanced technologies, including label-free imaging, high-speed laser editing, and machine learning, to create a scalable, automated system for producing patient-specific cells. By integrating AI, Wagner's team has developed a closed, cassette-based format that can process thousands of patient samples simultaneously. This breakthrough has the potential to significantly reduce costs, increase efficiency, and enable large-scale production of personalized therapies—offering the prospect of curing diseases like Parkinson’s, diabetes, and heart disease within the next decade.

Wagner’s vision for Cellino is encapsulated in their mission, Your Cells, Your Cure™, which underscores the company's commitment to making patient-specific regenerative therapies accessible to all. The platform’s ability to deliver personalized human cells at scale could revolutionize the treatment landscape for some of the toughest diseases, providing more precise, effective, and safer therapeutic options.

For healthcare leaders, investors, and innovators, this session offers a forward-looking exploration of how AI is not only transforming the manufacturing processes but also advancing the broader field of regenerative medicine. As the demand for personalized therapies grows, Wagner’s work at Cellino provides a compelling case for the role of AI in shaping the future of medicine—where scalable, automated solutions can unlock the potential of patient-specific treatments on a global scale.
buff.ly/3zEv3MP ... See MoreSee Less